drugset

Drugs / SCB-313

Follow last change May 2022 re-read 3 minutes ago

SCB-313

also known as Recombinant Human TRAIL-Trimer Fusion Protein · Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein

Protein / enzyme biologic

Developed for: peritoneal neoplasm · pleural neoplasm · peritoneal carcinomatosis
Investigated by: Sichuan Clover Biopharmaceuticals, Inc. · Clover Biopharmaceuticals AUS Pty

Trials 5

today NCT04123886 · Ph 1 NCT03869697 · Ph 1 NCT04051112 · Ph 1 NCT04047771 · Ph 1 NCT03443674 · Ph 1

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04123886	Jan 2020 → Sep 2021	pleural neoplasm	Sichuan Clover Biopharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT03869697	Nov 2019 → Nov 2021	pleural neoplasm	Clover Biopharmaceuticals AUS Pty	Completed	No outcome recorded
Phase 1	NCT04051112	Sep 2019 → Dec 2021	peritoneal neoplasm	Sichuan Clover Biopharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04047771	Sep 2019 → May 2022	peritoneal carcinomatosis	Sichuan Clover Biopharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 1	NCT03443674	Jun 2018 → May 2021	peritoneal neoplasm	Clover Biopharmaceuticals AUS Pty	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2019-05-07	Clover Biopharmaceuticals AUS Pty	Regulatory Clover Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China cloverbiopharma.com ↗ Clover Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China

All press releases naming this drug 9 releases

Date	Issuer	Release
2021-12-09	Clover Biopharmaceuticals AUS Pty	Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis cloverbiopharma.com ↗
2021-12-09	Ascentage Pharma Group Inc.	Ascentage and Clover to Jointly Develop APG-1387 plus SCB-313 ascentage.com ↗
2020-01-10	Clover Biopharmaceuticals AUS Pty	Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant Pleural Effusions (MPE) cloverbiopharma.com ↗
2019-11-21	Clover Biopharmaceuticals AUS Pty	Clover Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE) cloverbiopharma.com ↗
2019-09-29	Clover Biopharmaceuticals AUS Pty	Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites cloverbiopharma.com ↗
2019-09-10	Clover Biopharmaceuticals AUS Pty	Clover Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis cloverbiopharma.com ↗
2019-05-07	Clover Biopharmaceuticals AUS Pty	Clover Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China cloverbiopharma.com ↗
2018-06-18	Clover Biopharmaceuticals AUS Pty	Clover Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites cloverbiopharma.com ↗
2016-02-19	Clover Biopharmaceuticals AUS Pty	Clover initiates GLP studies on SCB-313 (Trail-Trimer) at National Shanghai Center for New Drug Safety Evaluation and Research. cloverbiopharma.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	SCB-313	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04047771 ↗ 4 NCT04051112 ↗ NCT03443674 ↗ NCT03869697 ↗ NCT04123886 ↗
Known as	Recombinant Human TRAIL-Trimer Fusion Protein	“SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via intrapleural injection” NCT03869697 ↗ 1 “SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein)” NCT04123886 ↗
Known as	Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein	“SCB-313, Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein” NCT04123886 ↗
Modality	Protein / enzyme biologic	“SCB-313 (recombinant human TRAIL-Trimer fusion protein)” NCT03443674 ↗
Route	Other	“via IP bolus injection” NCT03443674 ↗